Keppra, Antrim #31509, EPIC: LAB5398, SOFT: LEVET
Specimen Collection Criteria
Collect: One plain Red-top tube. (Minimum Whole Blood: 2.0 mL)
Do not use Serum Separator Tubes.
Time of Collection: Trough, just prior to the next dose.
Record the exact time of specimen collection on the tube or in the computer system.
Physician Office/Drawsite Specimen Preparation
Let specimens clot 30-60 minutes. Refrigerate (2-8°C or 36-46°F) the collection tube within two hours of collection. (Min: 2.0 mL blood)
Preparation for Courier Transport
Transport: Collection tube, refrigerated (2-8°C or 36-46°F). (Min: 2.0 mL blood)
- Serum Separator (SST) tubes.
- Severely lipemic or hemolyzed specimens.
Specimen Stability for Testing:
Room Temperature (20-26°C or 68-78.8°F): 2 hours
Refrigerated (2-8°C or 36-46°F): 8 hours
Frozen (-20°C/-4°F or below): 3 months
Specimen Storage in Department Prior to Disposal:
Frozen (-20°C/-4°F or below): 2 months
Royal Oak Toxicology Laboratory.
Sunday - Saturday.
Routine results available the same day as testing performed (1-2 days).
Therapeutic Range: 10-45 mcg/mL.
Critical Value: 70 mcg/mL.
The Therapeutic Range for Levetiracetam has not achieved adequate consensus, the values cited above are for general reference. Patients should be evaluated for therapeutic response and toxicity and managed individually.
Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS).
This test was developed and its performance characteristics determined by Beaumont Health. It has not been cleared or approved by the FDA. The Laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes and should not be regarded as investigational or for research.
Levetiracetam is not metabolized extensively and largely depends on renal elimination for clearance. Patients with diminished or changing renal function, the aging and dialysis patients may require dosage adjustment.
This assay is used for the therapeutic monitoring and toxicity assessment of levetiracetam. Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. Levetiracetam has been shown to exhibit bone marrow suppression. It may be appropriate to monitor white and red blood cell counts.
Antrim #31509, EPIC: LAB5398, SOFT: LEVET
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.
This directory currently reflects information only for specimens collected and/or processed at the Farmington Hills,
Grosse Pointe, Royal Oak, and Troy campuses.